Health News Spotlight: Lancet Refuses Senate Inquiry, Purdue Sentencing Delayed, and More
This article summarizes current health news, including The Lancet's refusal to participate in a Senate inquiry on COVID-19 origins, Purdue Pharma's delayed sentencing over opioid charges, initiatives by health insurers to streamline prior authorization, and the FDA's expedited drug program. Other highlights include drug sales expansion through new platforms and patent disputes in biotech.
The medical journal The Lancet has refused a request by the U.S. Senate to provide evidence regarding the origins of COVID-19, according to editor-in-chief Richard Horton. He confirmed the decision in an interview at the Reuters Pharma event.
Purdue Pharma's sentencing over opioid marketing charges has been postponed. A federal judge delayed the proceedings to allow more public involvement before accepting the company's guilty plea and imposing fines totaling $5.5 billion.
Efforts to standardize health insurance processes are gaining momentum with UnitedHealth and CVS Health reducing paperwork for prior authorizations. These developments are part of broader industry commitments to enhance transparency and efficiency.
(With inputs from agencies.)
Google News